Results 251 to 260 of about 130,065,242 (295)

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Integrating Artificial Intelligence with Emerging Pharmaceutical Technologies: Current Progress, Clinical Translation, and Future Challenges. [PDF]

Int J Mol Sci
Sharma P, Tiwari S, Park N, Szeleszczuk Ł.   +3 more
europepmc   +1 more source

Chimeric antigen receptor-engineered cell therapy for asthma: advances in targeting type 2 inflammation and translational challenges. [PDF]

Front Immunol
Niu Y, Jian C, Liu P, Wu M, Li H, Li X, Zhi L.   +6 more
europepmc   +1 more source

New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics. [PDF]

J Control Release
Zhou J, Li N, Liu R, Kabanov AV, Polacheck WJ, Nguyen J, Cao Y.   +6 more
europepmc   +1 more source

Driving precision medicine in testicular germ cell tumors: from preclinical models to clinical applications. [PDF]

Ther Adv Med Oncol
Tavares NT, Liu MY, Henrique R, Jerónimo C, Weiss RS, Lobo J.   +5 more
europepmc   +1 more source

Organoids: Current Applications and Future Directions. [PDF]

MedComm (2020)
Leng Y, Wang Y, Cao C, Deng F, Lian W, Chen X, Lin M, Zeng Z, Mo D, Li S, He Y, Yu Y, Pan H, Zhou P, Li R.   +14 more
europepmc   +1 more source

Considerations for the Development of in Vitro Dissolution Tests to Reduce or Replace Preclinical Oral Absorption Studies [PDF]

European Journal of Pharmaceutical Sciences, 2017
The pharmaceutical development of new chemical entities can be hampered by their solubility and/or dissolution limitations. Currently, these properties are characterised mostly during in vivo pre-clinical studies. The development of appropriate in vitro methods to study the solubility and dissolution properties in preclinical species would lead to a ...
Robert Taylor, Nikoletta Fotaki, Karl J Box   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

An in vitro model for preclinical testing of thrombogenicity of resorbable metallic stents

Journal of Biomedical Materials Research Part A, 2014
AbstractVascular stents that can biodegrade and disappear in time have been reported as a promising solution to the problems of late‐stent thrombosis and in‐stent restenosis. Iron alloys in particular have many advantages in terms of cytocompatibility and mechanical properties.
Emily K, Walker, Eric A, Nauman, Jean Paul, Allain, Lia A, Stanciu   +3 more
openaire   +2 more sources